Clinical observation of entecavir combined with Biejia decoction pill in treatment of DNA negative chronic hepatitis B liver fibrosis
Objective:To observe the curative effect of Entecavir combined with Biejia decoction pill on DNA-negative chronic hepatitis B.Methods:A retrospective study was conducted in 89 patients with long-term(more than 24 weeks)DNA-negative chronic hepatitis B patients,who were divided into mild,moderate and severe groups according to the grade of liver fibrosis.And then they were divided into two subgroups according to the treatment plan:the"monoantibody"group(Entecavir)and the"double antibody"group(Entecavir combined with Biejia decoction pill).Virus serology,biochemistry,and LSM values were compared between the"monoclonal antibody"group and the"double antibody"group after 24 weeks of treatment under different liver fiber grades.Results:There was no significant difference in virus serology index and LSM value between two groups(P＞0.05).After 24 weeks of treatment between the"double antibody"group and the"single antibody"group,there were statistically significant differences in γ-GT and TBil in the mild liver fiber grade(P＜0.05),and statistically significant differences in TBil in the moderate liver fibrosis grade(P＜0.05),and statistically significant differences in TBil in the severe liver fibrosis grade.There were no significant differences in ALT,AST,γ-GT,and TBil(P＞0.05).Conclusion:In the mild to moderate hepatic fiber grade,the efficacy of the"double antibody"group is better than that of the"single antibody"group.In the severe hepatic fiber grade,there is no significant difference in the efficacy of the two groups.
万方数据
维普
